CN111094981B - Pct和pro-adm作为监测抗生素治疗的标记物 - Google Patents

Pct和pro-adm作为监测抗生素治疗的标记物 Download PDF

Info

Publication number
CN111094981B
CN111094981B CN201880059114.XA CN201880059114A CN111094981B CN 111094981 B CN111094981 B CN 111094981B CN 201880059114 A CN201880059114 A CN 201880059114A CN 111094981 B CN111094981 B CN 111094981B
Authority
CN
China
Prior art keywords
sample
proadm
level
pct
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880059114.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111094981A (zh
Inventor
D·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59887051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111094981(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of CN111094981A publication Critical patent/CN111094981A/zh
Application granted granted Critical
Publication of CN111094981B publication Critical patent/CN111094981B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201880059114.XA 2017-09-13 2018-09-13 Pct和pro-adm作为监测抗生素治疗的标记物 Active CN111094981B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190913 2017-09-13
EP17190913.8 2017-09-13
PCT/EP2018/074724 WO2019053117A1 (en) 2017-09-13 2018-09-13 PCT AND PRO-ADM USED AS CONTROL MARKERS IN ANTIBIOTIC TREATMENT

Publications (2)

Publication Number Publication Date
CN111094981A CN111094981A (zh) 2020-05-01
CN111094981B true CN111094981B (zh) 2024-04-16

Family

ID=59887051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059114.XA Active CN111094981B (zh) 2017-09-13 2018-09-13 Pct和pro-adm作为监测抗生素治疗的标记物

Country Status (10)

Country Link
US (1) US20200264199A1 (https=)
EP (2) EP3682241B2 (https=)
JP (2) JP7258860B2 (https=)
CN (1) CN111094981B (https=)
BR (1) BR112020004150A2 (https=)
CA (1) CA3075442C (https=)
DK (1) DK3682241T4 (https=)
ES (1) ES2913298T5 (https=)
WO (1) WO2019053117A1 (https=)
ZA (1) ZA202001108B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094981B (zh) 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
RU2724186C1 (ru) * 2020-01-23 2020-06-22 Наталья Борисовна Гусева Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019230A2 (en) * 2007-08-03 2009-02-12 Brahms Aktiengesellschaft Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
WO2010139475A1 (en) * 2009-06-05 2010-12-09 B.R.A.H.M.S Gmbh Detection of bacterial infections in subjects suffering from dyspnea
CN101932572A (zh) * 2008-01-08 2010-12-29 默沙东有限公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
CN102822675A (zh) * 2010-03-08 2012-12-12 B.R.A.H.M.S有限公司 降钙素原用于在具有非特异性不适的患者中诊断细菌感染和指导抗生素治疗
CA2907467A1 (en) * 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
CN104126125A (zh) * 2012-03-08 2014-10-29 B.R.A.H.M.S有限公司 慢性阻塞性肺疾病患者的结果的预测

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
CN111094981B (zh) 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019230A2 (en) * 2007-08-03 2009-02-12 Brahms Aktiengesellschaft Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
CN101790687A (zh) * 2007-08-03 2010-07-28 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
CN103123359A (zh) * 2007-08-03 2013-05-29 B.R.A.H.M.S有限公司 降钙素原（pct）在患原发性非传染疾病的患者的风险分级和预后中的应用
CN101932572A (zh) * 2008-01-08 2010-12-29 默沙东有限公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
WO2010139475A1 (en) * 2009-06-05 2010-12-09 B.R.A.H.M.S Gmbh Detection of bacterial infections in subjects suffering from dyspnea
CN102822675A (zh) * 2010-03-08 2012-12-12 B.R.A.H.M.S有限公司 降钙素原用于在具有非特异性不适的患者中诊断细菌感染和指导抗生素治疗
CN104126125A (zh) * 2012-03-08 2014-10-29 B.R.A.H.M.S有限公司 慢性阻塞性肺疾病患者的结果的预测
CA2907467A1 (en) * 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections;SILVIA ANGELETTI 等;《APMIS》;第123卷;第740–748页 *
降钙素原联合肾上腺髓质素前体中段肽在脓毒症诊断中的应用;雷艳梅;周潇;马建国;罗浩元;;广东医学(第09期);第1383-1385页 *

Also Published As

Publication number Publication date
ZA202001108B (en) 2022-08-31
CA3075442C (en) 2024-04-02
EP3682241A1 (en) 2020-07-22
EP4027145A1 (en) 2022-07-13
RU2020111718A3 (https=) 2022-02-01
WO2019053117A1 (en) 2019-03-21
RU2020111718A (ru) 2021-10-13
EP3682241B2 (en) 2025-09-10
US20200264199A1 (en) 2020-08-20
JP7258860B2 (ja) 2023-04-17
DK3682241T4 (da) 2025-10-06
JP2020533603A (ja) 2020-11-19
DK3682241T3 (da) 2022-05-16
ES2913298T3 (es) 2022-06-01
CN111094981A (zh) 2020-05-01
CA3075442A1 (en) 2019-03-21
EP3682241B1 (en) 2022-03-30
WO2019053117A8 (en) 2021-01-21
BR112020004150A2 (pt) 2020-09-08
ES2913298T5 (en) 2026-01-02
JP2023095851A (ja) 2023-07-06

Similar Documents

Publication Publication Date Title
JP2025019061A (ja) 術後有害事象の診断または予後
AU2021251382B2 (en) Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS)
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
US20240393352A1 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant